Suven Pharmaceuticals Q1 FY27 Results: Revenue Rs 3 Cr, PAT Rs 127 Cr and Key Highlights

Suven Pharmaceuticals Q1 FY27 results were announced on August 6, 2026, on a Consolidated basis. Suven Pharmaceuticals Q1 FY27 results show revenue grew +91.02% year-on-year to Rs 3 Cr from Rs 1 Cr in Q1 FY26, reflecting sustained demand in the Pharmaceuticals segment. The broader Nifty Pharma index also reflected mixed sentiment during the quarter.

Operating profit contracted -158.38% YoY to Rs -134 Cr from Rs -52 Cr, reflecting margin pressure from input costs and competitive dynamics. The company reported a net loss of Rs 127.00 Cr in Q1 FY27, narrowing from a loss of Rs 51.00 Cr in Q1 FY26, indicating a gradual recovery trajectory. The quarterly numbers offer a detailed picture of how the company is navigating the current pharmaceuticals environment.

Click Here – Get Free Investment Predictions

Suven Pharmaceuticals Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Suven Pharmaceuticals Revenue	3	1	+91.02%
Operating Profit	-134	-52	-158.38%
Net Profit (PAT)	-127	-51	-147.71%
Reporting Basis	Consolidated

Suven Pharmaceuticals Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Suven Pharmaceuticals Q1 FY27 results reflect pressure fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 3 Cr for the April to June 2026 quarter.

Operating profit stood at Rs -134 Cr, contracting -158.38% YoY. Management is implementing cost reduction measures to restore operating leverage.

The net loss of Rs 127.00 Cr in Suven Pharmaceuticals Q1 FY27 results indicates that the turnaround is still in progress. Investors monitoring Suven Pharmaceuticals Q1 FY27 results will note this as a key milestone for FY27 tracking.

Key Business Factors in Suven Pharmaceuticals Q1 FY27 Results

Revenue Growth Momentum in the Pharmaceuticals Segment

Suven Pharmaceuticals Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +91.02% YoY to Rs 3 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.

Operating Profit Under Pressure from Cost Headwinds

Operating profit in Suven Pharmaceuticals Q1 FY27 results came in at Rs -134 Cr (-158.38% YoY), weighed down by input cost inflation, employee expenses, and competitive pricing dynamics.

Net Loss and Path Toward Profitability

Suven Pharmaceuticals Q1 FY27 results reflect a net loss of Rs 127.00 Cr. Management has outlined a roadmap to profitability through operational restructuring, debt reduction, and revenue scaling in higher-margin product lines.

Dividend Details

No dividend was announced along with Suven Pharmaceuticals Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.

FY27 Outlook for Suven Pharmaceuticals

Following Suven Pharmaceuticals Q1 FY27 results, management has reiterated its recovery roadmap, targeting operational efficiencies and revenue diversification to return to profitability. The pace of recovery in the Pharmaceuticals segment and macro tailwinds will be key monitorables. Investors tracking Suven Pharmaceuticals Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.

Suven Pharmaceuticals Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Suven Pharmaceuticals live price and get daily stock recommendations.

Suven Pharmaceuticals shares were trading lower at Rs 317.8 (-2.68%) on August 6, 2026, following the declaration of Suven Pharmaceuticals Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 317.8 on the results date, with a 52-week range reflecting the broader market sentiment toward the pharmaceuticals sector.

Key Risks for Suven Pharmaceuticals

Sector-Specific Headwinds

US FDA regulatory actions, pricing pressure in generics, and USFDA import alerts remain core risks.

Valuation and Earnings Risk

Sustained margin compression and earnings visibility remain key concerns for investors in the near term.

Operational and Financial Risk

Subsidiary-level losses or underperformance in overseas operations could drag consolidated PAT lower.

Conclusion

Suven Pharmaceuticals Q1 FY27 results reflect near-term operational challenges with revenue at Rs 3 Cr and a net loss of Rs 127.00 Cr on a Consolidated basis. The management's ability to execute its recovery plan will determine the stock's re-rating potential. Investors are advised to monitor quarterly progress before making investment decisions.

Frequently Asked Questions on Suven Pharmaceuticals Q1 FY27 Results

When were Suven Pharmaceuticals Q1 FY27 results declared?

Ans. Suven Pharmaceuticals Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Consolidated basis.

What was Suven Pharmaceuticals revenue in Q1 FY27?

Ans. Suven Pharmaceuticals Q1 FY27 results show revenue of Rs 3 Cr, +91.02% compared to Rs 1 Cr in Q1 FY26.

What was Suven Pharmaceuticals PAT in Q1 FY27?

Ans. Net loss in Suven Pharmaceuticals Q1 FY27 results was Rs 127 Cr, -147.71% year-on-year.

Did Suven Pharmaceuticals declare a dividend in Q1 FY27?

Ans. No dividend was declared alongside Suven Pharmaceuticals Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.

What is the FY27 outlook for Suven Pharmaceuticals?

Ans. Suven Pharmaceuticals management has outlined a focus on operational restructuring and return to profitability for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.

How did the Suven Pharmaceuticals stock react to Q1 FY27 results?

Ans. Suven Pharmaceuticals shares were trading lower at Rs 317.8 (-2.68%) on August 6, 2026, following the Suven Pharmaceuticals Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.